There have been many clinical trials investigating the use and benefits of ADSCs. These studies involve soft tissue regeneration, ischemic injuries, skeletal tissue repair, myocardial infarction, and immune disorders (Crohn’s disease, lupus, arthritis, multiple sclerosis and others). Other therapeutic uses include treatment of intervertebral disc degeneration and pulmonary disease. Due to their origin, ADSCs have mesodermal potential, which includes bone regeneration, fat reconstruction, and tissue regeneration.
Studies have shown that ADSCs have regenerative bone effects in animal subjects and humans. Regarding avascular necrosis of the femoral head (thigh bone ball), animal studies show that ADSC enhance osteogenesis (bone formation) and microstructure of the osteonecrotic tissue two months after injections. Current animal research shows very promising results for post concussion syndrome.
Fat cells also have effective anti-scarring ability. In a study where adipose cells were used after injury, they were found to attenuate the formation of hypertrophic scars by secretion of anti-fibrosis cytokines, which was show in rabbit ear scar models. The researchers injected ADSCs into a lesion and evaluated the scarring months later. Regarding cartilage regeneration, ADSCs were found to repair cartilage defects in studies. The results suggested that ADSCs and chondrocytes may have the potential to repair and regenerate cartilage in tissue engineering procedures.
Recent research performed by CSN has shown utility of ADSCS for a number of neurological disorders. For instance, over the course of two years, multiple sclerosis patients experienced a 52% reduction in MISS-29 scores over 2 years after stem cell therapy. The success rate for this disease was 73%.
In addition to multiple sclerosis, success rates have risen for disorders such as stroke (55%), Parkinson’s Disease (64.8%), Muscular Dystrophy (64.3%), and Cerebral Palsy (77.4%) thanks to ADSCS therapy.